Business
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
BOSTON, September 29, 2025--PureTech Presents New Data from Deupirfenidone Phase 2b Open-Label Extension, Further Supporting Potential to Serve as New Standard of Care in IPF
About this update from Puretech Health Plc
[{"type":"image","alt":"Lung Function Stabilized in Patients who Switched from Placebo or Pirfenidone to Deupirfenidone 825 mg TID","displaySize":"","headline":null,"caption":"Lung Function Stabilized in Patients who Switched from Placebo or Pirfenidone to Deupirfenidone 825 mg TID","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/f9af7a9eb54415cf6c8016375c349c9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sS5ed.qwRFrDg4rg7jHxRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/f9af7a9eb54415cf6c8016375c349c9a","width":480,"height":270}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":7367,"height":2362,"url":"https://media.zenfs.com/en/business-wire.com/596f97f95e798453d4255d5c30c2ecaa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EzytpKCK1vk4XMs1DsOGcg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/596f97f95e798453d4255d5c30c2ecaa","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/MQgvVKklaZtHAMQ1NnpMKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/596f97f95e798453d4255d5c30c2ecaa","width":1200,"height":385}}},{"type":"text","content":"Patients who switched from placebo or pirfenidone to deupirfenidone in the open-label extension study achieved stabilization of lung function with favorable tolerability","length":169,"tagName":"p","attribs":{}},{"type":"text","content":"Findings further substantiate safety and efficacy results from the randomized, placebo- and active-controlled 26-week trial and highlight opportunity to address patients inadequately served by current therapies","length":210,"tagName":"p","attribs":{}},{"type":"text","content":"Regulatory engagement underway; update on Phase 3 trial design expected in Q4 2025","length":82,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, September 29, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into va...